• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Drug costs projected to rise 3% to 5% in 2014

Report: Drug costs projected to rise 3% to 5% in 2014

March 10, 2014
CenterWatch Staff

Costs for medications are expected to rise 3% to 5% in all healthcare settings in 2014, according to a report published online by the American Journal of Health-System Pharmacy (AJHP), the professional journal of the American Society of Health-System Pharmacists (ASHP).

Prescription drugs account for approximately 11% of overall U.S. healthcare expenditures. As with other healthcare expenditures, growth in prescription drug spending has lessened in recent years, with a 0.7% decrease in spending during the 12 months ending Sept. 30, 2013, compared with 2012. The report expects a reversal of this trend in 2014, projecting a 3% to 5% increase in drug expenditures across all settings, a 5% to 7% increase in expenditures for clinic-administered drugs and a 1% to 3% increase in hospital drug expenditures.

“Our projections for 2014 indicate a clear reversal of the downward growth in prescription drug expenditures we have seen over the last several years,” said Glen T. Schumock, PharmD, Ph.D., lead author of the report National Trends in Prescription Drug Expenditures and Projections for 2014.  “Drug expenditure trends will remain dynamic, and so health systems will need to carefully monitor local drug use patterns.”

These increases in expenditures are influenced by a variety of factors, according to the report, including new drug approvals and patent expirations.  Using data provided by IMS Health, the authors report several trends in prescription drug spending, including:

  • Clinics and nonfederal hospitals experienced increased drug spending (4.5% and 1.8% growth, respectively) in 2013 relative to 2012, while decreased expenditures were seen in federal facilities (-13.7%) and in long-term care (-4.2%), mail order (-1.9%) and retail pharmacy (-0.3%) sectors.
  • Changes in expenditures for specific medications, drug classes and therapeutic categories. These included a significant decrease in expenditures in all settings for oxycodone; a significant increase in expenditures for influenza vaccines in the clinic, which may be due to new vaccine formulations and recommendations; a decrease in the expenditure growth rate for anti-cancer drugs (from 2012 to 2013), although anti-cancer drugs remain the top expenditure for hospitals and clinics; and changes in the availability of generic products, with fewer first-time generic drugs expected to reach the market in 2014.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing